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Abstract
Purpose Diethylenetriamine-pentaacetic acid (DTPA)-cou-
pled minigastrins are unsuitable for therapeutic application
with the available β-emitting radiometals due to low
complex stability. Low tumour-to-kidney ratio of the known
radiopharmaceuticals is further limiting their potency. We
used macrocyclic chelators for coupling to increase complex
stability, modified the peptide sequence to enhance radiolytic
stability and studied tumour-to-kidney ratio and metabolic
stability using 111In-labelled derivatives.
Methods Gastrin derivatives with decreasing numbers of
glutamic acids were synthesised using 111In as surrogate for
therapeutic radiometals for in vitro and in vivo studies.
Gastrin receptor affinities of the natIn-metallated compounds
were determined by receptor autoradiography using 125I-
CCK as radioligand. Internalisation was evaluated in AR4-2J
cells. Enzymatic stability was determined by incubating the
111In-labelled peptides in human serum. Biodistribution was
performed in AR4-2J-bearing Lewis rats.
Results IC50 values of the
natIn-metallated gastrin deriva-
tives vary between 1.2 and 4.8 nmol/L for all methionine-
containing derivatives. Replacement of methionine by
norleucine, isoleucine, methionine-sulfoxide and methionine-
sulfone resulted in significant decrease of receptor affinity
(IC50 between 9.9 and 1,195 nmol/L). All cholecystokinin
receptor affinities were >100 nmol/L. All 111In-labelled
radiopeptides showed receptor-specific internalisation.
Serum mean-life times varied between 2.0 and 72.6 h,
positively correlating with the number of Glu residues. All
111In-labelled macrocyclic chelator conjugates showed
higher tumour-to-kidney ratios after 24 h (0.37–0.99)
compared to 111In-DTPA-minigastrin 0 (0.05). Tumour wash
out between 4 and 24 h was low. Imaging studies confirmed
receptor-specific blocking of the tumour uptake.
Conclusions Reducing the number of glutamates increased
tumour-to-kidney ratio but resulted in lower metabolic stability.
The properties of the macrocyclic chelator-bearing derivatives
make them potentially suitable for clinical purposes.
Keywords Cholecystokinin . Gastrin .Minigastrin .
Macrocyclic chelator . Medullary thyroid carcinoma
Introduction
Gastrin is a 34-, 17- or 14-amino-acids-containing peptide that
regulates acid secretion and proliferation of the gastric mucosa
[1]. It is synthesised in the gastric G cells as a preprohor-
mone and is post-translationally cleaved to form a family of
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peptides with identical carboxytermini [2]. Gastrin binds to
the cholecystokinin (CCK) receptors, which are found
physiologically on parietal and enterochromaffin-like cells.
The two receptors of the gastrin-CCK family that
consists of the CCK and the gastrin receptor are G-
protein-coupled receptors [3]. Gastrin shows low affinity
to the CCK receptor, which is mainly expressed in the gall
bladder, gastric smooth muscle, pancreas and peripheral
nerve system. Conversely, gastrin has high affinity to the
gastrin receptor, which is mainly expressed in the gastric
mucosa, endocrine pancreas and brain [4, 5]. Gastrin
receptors are also overexpressed in medullary thyroid
cancer [6], small cell lung cancer, stromal ovarian cancer,
gastrointestinal adenocarcinoma and in neuroendocrine
tumours [7–10]. Therefore, the gastrin receptor appears to
be a promising target for diagnostic and therapeutic
application of radiolabelled gastrin analogues [11–14].
Non-sulfated CCK analogues or, alternatively, minigastrin
analogues, have recently been introduced for imaging and
treatment of medullary thyroid carcinoma patients [15–22].
Derivatives for labelling with 111In or 90Y employed the
acyclic chelator diethylenetriamine-pentaacetic acid (DTPA);
however, the [90Y-DTPA] monoamide complexes are not
stable enough for targeted radionuclide therapy [23]. To
increase the complex stability, a DTPAGlu chelator was
employed [21]; however, the low tumour-to-kidney ratio
restricted its therapeutic use [18, 19, 22]. Alternatively,
macrocyclic chelators like 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) or 1-(1-carboxy-3-carboxy-
propyl)-1,4,7,10-tetraazacyclododecane-4,7,10-triacetic acid
(DOTAGA) provide higher stability compared to acyclic
chelators [24], whereas DOTAGA provides faster labelling
kinetics [25, 26].
Thus, we coupled minigastrins with macrocyclic chela-
tors to increase their complex stability. We also modified
the peptide sequence to increase the important tumour-to-
kidney ratio and radiolytic stability.
Materials and methods
Synthesis of chelator–peptide conjugates
All chemicals were commercially available and used
without further purification. DOTAGA(tBu)4 and DOTA
(tBu)3 were synthesised as previously described [24, 27].
DTPA(tBu)3 was obtained commercially (Mallinckrodt
Medical, USA). All peptides were assembled on Rink
amide MBHA resin (0.6 mmol/g; NovaBiochem, Switzer-
land) using solid phase peptide synthesis on a semiauto-
matic peptide synthesiser (Rink Combichem Technologies,
Switzerland). Three equivalents of Fmoc-protected amino
acids (NovaBiochem, Switzerland) based on resin loading
with 3.3 equivalents of N-hydroxy-benzotriazole, 3.3 equiv-
alents of N,N′-diisopropylcarbodiimide and five equivalents
of N-ethyldiisopropylamine were used for coupling (reaction
time: 45 min). Fmoc was removed with 20% piperidine/N,N-
dimethylformamide. The tBu-protected chelator was at-
tached using two equivalents of the prochelator with two
equivalents of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetrame-
thyluronium hexafluoro-phosphate. Deprotection and cleav-
age from resin was performed by adding a solution of 91% of
trifluoroacetic acid (TFA), 3% H2O, 5% thioanisole and 1%
of triisopropyl-silane. The crude product was precipitated
using a 1:1 mixture of diisopropylether/petrolether. Purifica-
tion was done by preparative high-performance liquid
chromatography (HPLC) using Uptisphere UP5ODB/25M
column (Laubscher Labs, Switzerland), Bischof 2250 HPLC
pumps and λ-1010 UV-detector (Metrohm AG, Switzerland).
The products were lyophilised and characterised by ESI-MS
(Waters ZMD; Waters-Micromass, USA, with HP1100
Quaternary LC pump; Hewlett Packard, USA) or MALDI-
MS (Voyager sSTR equipped with Nd/YAG laser (355 nm);
Applied BioSystems, USA). Purity was checked by HPLC
(Macherey-Nagel Nucleosil 120-3 C18 reversed phase col-
umn on 1050 HPLC system; Hewlett Packard, Germany,
Berthold LB506 Cl γ-detector, Germany) with the gradient:
eluent A: 0.1% TFA in water, eluent B: acetonitrile; 0 min
95% A, 30 min 55% A, 32 min 0% A, 34 min 0% A; flow:
0.75 mL/min; λ: 214 nm.
Radiolabelling
Radiolabelling was performed as previously described [28].
Three hundred microlitres of a 0.4 mol/L sodium acetate
buffer pH 5 was added to an aliquot of 5 μg of the
corresponding peptide–chelator conjugate, followed by 37
MBq 111InCl3 (Mallinckrodt, The Netherlands) and heated
for 30 min at 95°C. For internalisation and serum stability
studies, five equivalents of natInCl3 were added and heated
again for 30 min to 95°C, and excess natInCl3 was separated
by solid phase extraction using a SepPak C18 cartridge
(Waters, Switzerland). The radiopeptide was immobilised on
the cartridge; excess of natInCl3 was rinsed off with water.
Finally, the product was eluted with methanol, evaporated to
dryness and reconstituted in water. Quality control after
radiolabelling was performed using the HPLC system
described above and the following gradient: eluent A: 0.1%
TFA in water, eluent B: acetonitrile; 0 min 95% A, 5 min
95% A, 10 min 0% A, 15 min 0% A; flow: 0.75 mL/min.
Binding affinity studies on CCK- or gastrin-expressing
tissues
Binding affinities were evaluated as previously described
[29] in surgically extracted human tumour tissues selected
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from previous experiments to express either cholecystoki-
nin and gastrin receptors [5, 7]. Increasing amounts of natIn-
labelled minigastrin derivatives were added to the 125I-
labelled D-Tyr-Gly-Asp-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-
Phe-amide (125I-CCK) containing incubation medium to
generate competitive inhibition curves. Tissue slides were
exposed to Biomax MR films (Kodak) for 1–7 days.
Autoradiograms were quantified using tissue standards for
iodinated compounds (Amersham, UK) [30].
Enzymatic stability in human serum
After labelling with 111In/natInCl3, 40 pmol of each compound
was added to 2 mL fresh human blood serum and incubated
at 37°C and 5% CO2; 150 μL of this solution was removed
at different time intervals and added to 150 μL of ethanol.
The precipitate was separated by centrifugation (10 min,
1,850×g, 4°C). The supernatant was analysed by HPLC as
described above.
Cell culture and in vitro internalisation assay on AR4-2J
cells
Gastrin receptor-positive AR4-2J rat pancreatic tumour
cells [31] were kept in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum,
amino acids and vitamins (Amimed, BioConcept, Switzer-
land). The internalisation experiments were performed as
previously described [32, 33]. One million AR4-2J cells
were washed with DMEM and allowed to rest for 1 h at 37°C
in 1.2 mL of medium. An amount of 0.25 pmol (2.8 kBq) of
the 111In/natIn-labelled chelator–peptide conjugates was
added to a final concentration of 0.167 nmol/L, and cells
were incubated at 37°C in 5% CO2. To study non-receptor-
specific uptake, >104-fold excess of unlabelled DOTA-
minigastrin 11 (3 nmol/well) was added. The internalisation
was stopped after different incubation times (30 min, 1, 2 and
4 h) by removal of the medium. Cells were washed twice
with phosphate-buffered saline (pH 7.2, 4°C) and then twice
with glycine buffer (5 min, 0.05 mol/L glycine, pH 2.8, 4°C)
to discriminate between cell surface-bound (acid releasable)
and internalised radioligand. Cells were then incubated with
1 mol/L NaOH (10 min, 37°C) to release them from the
plate. All fractions were collected in triplicates, and
quantitative γ-counting was done using a COBRA II, D
5003 γ-system well counter (Canberra Packard, USA).
Biodistribution and SPECT/CT imaging in AR4-2J-bearing
Lewis rats
All animal experiments were approved and performed
according to the national regulations for animal treatment
(Bundesamt für Veterinärwesen, approval no. 789). Ten
million AR4-2J rat pancreatic tumour cells were subcuta-
neously implanted in the right posterior limb of 6-week-old
Lewis rats (Harlan, The Netherlands). Two weeks after
inoculation of the tumour cells, 0.1 nmol (1.1 MBq) of the
corresponding 111In-labelled chelator–peptide conjugate
(dissolved in 200 μL of saline supplemented with 0.1%
human serum albumin) was injected intravenously under
inhalation anaesthesia (3 vol.% isoflurane with 0.6 L O2/
min). To determine non-specific tumour uptake, 100 μg
(71.3 nmol) unlabelled DOTA-minigastrin 11 was added to
the injection solution. The rats (in groups of three to five
animals, 160–180 g body weight and 6–15 mm tumour
diameter) were sacrificed 4 or 24 h post-injection, respec-
tively, under anaesthesia.
Organs of interest were collected, rinsed of excess blood,
plotted dry and weighed. The radioactivity of the different
samples was quantified on a γ-counter.
Four hours after injection of the radioligand, the sacrificed
animals were placed on a SPECT/CT-camera (Symbia T2,
Siemens, Germany) for the acquisition of images. Iteratively
reconstructed SPECT images (four subsets, eight iterations)
were combined with three-dimensional reconstructed images
from the spiral CT (1.25 mm slices, 1.2 mm reconstruction
increment, 130 kV, 48 mA s).
Statistical methods
Discrete variables are expressed as counts (percentage) and
continuous variables as mean ± standard deviation, unless
stated otherwise. A first-order decay model was used to
calculate serum mean-life time values. Receptor-specific
internalisation was calculated as difference between non-
blocked and blocked uptake and expressed as percentage of
applied activity. Organ uptakes were calculated and
expressed as percentage of injected activity per gram tissue
(%IA/g). A linear regression model was employed to
examine the association of internalisation rates, binding
affinities, tumour uptake and kidney uptake. p values of
<0.05 were considered to be statistically significant.
Results
Synthesis of chelator–peptide conjugates
The following compounds were synthesised: DOTA-mini-
gastrin 9 (minigastrin 9: DGlu-Glu-Glu-Ala-Tyr-Gly-Trp-
Met-Asp-Phe-NH2), DOTA-minigastrin 10 (minigastrin 10:
DGlu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), DOTA-min-
igastrin 11 (minigastrin 11: DGlu-Ala-Tyr-Gly-Trp-Met-Asp-
Phe-NH2), DOTAGA-minigastrin 11 and DTPA-minigastrin
11 (Fig. 1). In addition, DOTA-minigastrin 11-based com-
pounds, with the amino acid methionine replaced by
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isoleucine (Ile), norleucine (Nle), methionine-sulfoxide (Met
(O)) or methionine-sulfone (Met(O2)) were synthesised. All
conjugates showed purities >95% as confirmed by HPLC;
identities were confirmed by mass spectroscopy. Both
synthesised DTPA-conjugates showed shorter HPLC reten-
tion times than the DOTA-conjugates (Table 1).
Radiolabelling with 111InCl3
Radiolabelling of all chelator–peptide conjugates with 111In
and quality control using HPLC resulted in the following
retention times and radiochemical purities: [111In-DTPA]-
minigastrin 0 (retention time: 21.82 min; radiochemical
purity: 99.0%); [111In-DTPA]-minigastrin 11 (22.30 min;
99.9%); [111In-DOTA]-minigastrin 9 (22.90 min; 95.9%);
[111In-DOTA]-minigastrin 10 (22.97 min; 97.8%); [111In-
DOTA]-minigastrin 11 (22.90 min; 97.5%); [111In-
DOTAGA]-minigastrin 11 (22.85 min; 99.4%).
Binding affinity studies on CCK-positive tissues
Receptor binding affinities to cholecystokinin and gastrin
receptor-positive tumour cells are expressed as IC50 values,
describing the concentration of the tested substance needed
Table 1 Mass spectrometry and HPLC data of the studied minigastrins
Compound Calculated mass (g/mol) Observed massa Purityb (%) Retention timec (min)
DOTAGA-minigastrin 11 1,474.6 1,475.6, [M+H]+; 85% 97.3 27.88
1,497.3, [M+Na]+; 100%
1,519.6, [M+2 Na–H]+; 46%
DOTA-minigastrin 11 1,402.6 1,403.6, [M+H]+; 100% 98.2 27.85
1,425.4, [M+Na]+; 55%
1,441.3, [M+2 Na–H]+; 30%
DOTA-minigastrin 10 1,531.6 1,532.4, [M+H]+; 100% 96.8 27.62
1,554.5, [M+Na]+; 25%
DOTA-minigastrin 9 1,660.7 1,661.5, [M+H]+; 100% 97.8 27.47
1,683.5, [M+Na]+; 25%
DTPA-minigastrin 11 1,391.5 1,392.4, [M+H]+; 18% 96.3 26.84
1,414.4, [M+Na]+; 100%
1,436.3, [M+2 Na]+; 38%
DTPA-minigastrin 0 2,036.8 2,059.3, [M+Na]+; 100% 95.8 26.63
2,075.2, [M+K]+; 55%
aAssessed by mass spectrometry, mass in grams per mole, interpretation, relative abundance
b Evaluated by HPLC (gradient I)
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to inhibit the binding of 125I-CCK by 50%. These IC50
values are listed in Table 2. All compounds having the
native seven carboxyterminal amino acids showed IC50
values <5 nmol/L to the gastrin receptor and IC50 values
>100 nmol/L to the cholecystokinin receptor. IC50 values to
the gastrin receptor were reduced when the amino acid
methionine was replaced by norleucine (factor 2), isoleucine
(factor 42), methionine-sulfone and methionine-sulfoxide
(both factor >200).
Enzymatic stability in human blood serum
Time-dependent degradation of the minigastrin analogues
are presented in Fig. 2. The corresponding mean-life times
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eFig. 2 Serum stabilities of the
111In-labelled minigastrins: filled
squares [111In-DTPA]-minigastrin
0, grey triangles [111In-DOTA]-
minigastrin 9, inverted grey tri-
angles [111In-DOTA]-minigastrin
10, plus signs = [111In-
DOTAGA]-minigastrin 11, grey
circles [111In-DTPA]-minigastrin
11, filled diamonds [111In-
DOTA]-minigastrin 11,
ex marks [111In-DOTA, Nle15]-
minigastrin 11
Table 2 Gastrin and cholecystokinin receptor binding affinities of the studied minigastrins
Compound n Binding affinity to the gastrin
receptor
Binding affinity to the cholecystokinin
receptor
[DTPA]- minigastrin 0 6 0.98±0.4 >100
[In-DOTA]-minigastrin 9 2 1.2±0.4 >100
[In-DOTA]-minigastrin 10 2 2.5±0.1 >100
[In-DOTA]-minigastrin 11 6 4.8±0.7 >100
[In-DOTAGA]-minigastrin 11 2 3.4±2.0 >100
[In-DTPA]-minigastrin 11 3 3.9±0.6 –
[In-DOTA]-DGlu-Ala-Tyr-Gly-Trp-Nle15-Asp-Phe-NH2 2 9.9±0.1 >1,000
[In-DOTA]-DGlu-Ala-Tyr-Gly-Trp-Ile15-Asp-Phe-NH2 2 200±5.0 >1,000
[In-DOTA]-DGlu-Ala-Tyr-Gly-Trp-Met(O2)
15-Asp-Phe-NH2 2 1,195±760 >1,000
[In-DOTA]-DGlu-Ala-Tyr-Gly-Trp-Met(O)15-Asp-Phe-NH2 2 1,096±116 >1,000
Binding affinities are expressed as IC50 values (nanomoles per litre) in mean ± SD
n Number of experiments
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of the radiolabelled compounds in human blood serum
were as follows: [111In-DTPA]-minigastrin 0 (72.6 h), [111In-
DOTA]-minigastrin 9 (15.4 h), [111In-DOTAGA]-minigastrin
11 (7.2 h), [111In-DOTA]-minigastrin 10 (5.8 h), [111In-
DTPA]-minigastrin 11 (2.6 h), [111In-DOTA]-minigastrin 11
(2.4 h), [111In-DOTA, Nle15]-minigastrin 11 (2.0 h).
In vitro internalisation into AR4-2J cells
The internalised fractions, expressed as percent of the
injected activity per 1 million cells over a 4-h period, are
shown in Table 3. The 4-h values of all compounds
significantly decreased to <0.5% after addition of excess of
unlabelled DOTA-minigastrin 11 (p<0.001). The surface-
bound radioligand did not exceed 2% of the added
radioactivity after 4 h.
Biodistribution studies in AR4-2J-bearing Lewis rats
Organ uptakes are listed in Table 4; a detailed list is provided
in Supplemental Table 1. [111In-DTPA]-minigastrin 0 (0.64±
0.11% I.A./g) and [111In-DOTA]-minigastrin 9 (0.68±
0.40%) showed 4-h tumour uptake values distinctly higher
compared to [111In-DOTA]-minigastrin 10 (0.32±0.15%),
[111In-DOTA]-minigastrin 11 (0.31±0.04%) and [111In-
DOTAGA]-minigastrin 11 (0.34±0.09%). The difference in
tumour uptake was not significant between [111In-DOTA]-
minigastrin 11 and [111In-DOTAGA]-minigastrin 11 (p=
0.71). High tumour uptakes were found along with high
binding affinities (r=0.85, Fig. 3a), high internalisation rates
(r=0.71, Fig. 3b) and high blood serum stabilities (r=0.67,
Fig. 3c). Coinjection of excess of unlabelled DOTA-mini-
gastrin 11 significantly reduced the uptake of [111In-DOTA]-
minigastrin 11 into the tumour by 87% (Table 4) and of
[111In-DOTA]-minigastrin 9 by 84%. The uptake into the
stomach was reduced by 84% for [111In-DOTA]-minigastrin
11 and by 93% for [111In-DOTA]-minigastrin 9. [111In-
DTPA]-minigastrin 0 showed the highest kidney uptake after
4 h (8.66±0.44%), followed by [111In-DOTA]-minigastrin 9
(1.46±0.23%), [111In-DOTA]-minigastrin 11 (0.36±0.07%),
[111In-DOTAGA]-minigastrin 11 (0.33±0.01%) and [111In-
DOTA]-minigastrin 10 (0.32±0.02%; Table 4). The kidney
uptake was negatively correlated to the overall compound
Table 3 Internalisation rates after 4-h incubation
Compound Internalisation
rate
n pa
[111In-DTPA]-minigastrin 0 14.1±0.6% 3 –
[111In-DOTA]-minigastrin 9 11.0±2.3% 12 0.002
[111In-DOTA]-minigastrin 10 6.4±1.0% 9 0.000
[111In-DOTA]-minigastrin 11 10.4±0.8% 9 0.001
[111In-DOTAGA]-minigastrin 11 9.7±3.1% 12 0.001
[111In-DTPA]-minigastrin 11 8.9±1.2% 9 0.000
[111In-DOTA]-[Nle15]-minigastrin 11 7.5±0.5% 3 0.009
Internalisation rates are expressed in percentage of injected activity
per million cells in mean ± SD
n Number of experiments
a p vs. [111 In-DTPA]-minigastrin 0
Table 4 Biodistribution data of the studied minigastrins
Compound Values Tumour Stomach Pancreas Kidney Tumour/
kidney
Tumour/
stomach
[111In-DTPA]-minigastrin 0 4 h (n=5) 0.64±0.11 0.16±0.01 0.01±0.00 8.66±0.44 0.07 3.88
24 h (n=2) 0.58±0.22 0.18±0.00 0.03±0.02 10.5±4.11 0.05 3.25
[111In-DOTA]-minigastrin 9 4 h (n=5) 0.68±0.40* 0.14±0.05 0.01±0.00 1.46±0.23** 0.46 11.1
4 h blockeda (n=5) 0.11±0.00*** 0.01±0.00 0.00±0.00 1.13±0.13
24 h (n=3) 0.45±0.31 0.05±0.02 0.01±0.00 1.22±0.55 0.37 9.55
[111In-DOTA]-minigastrin 10 4 h (n=5) 0.32±0.15** 0.06±0.01 0.01±0.01 0.32±0.02** 1.01 5.23
24 h (n=3) 0.28±0.22 0.02±0.01 0.01±0.00 0.38±0.01 0.73 12.1
[111In-DOTA]-minigastrin 11 4 h (n=4) 0.31±0.04** 0.05±0.01 0.01±0.00 0.36±0.07** 0.89 6.42
4 h blockeda (n=5) 0.04±0.01**** 0.01±0.00 0.00±0.00 0.31±0.02
24 h (n=3) 0.34±0.01 0.02±0.01 0.01±0.00 0.34±0.04 0.99 14.8
[111In-DOTAGA]-minigastrin 11 4 h (n=4) 0.34±0.09** 0.07±0.02 0.00±0.00 0.33±0.01** 1.02 4.98
24 h (n=3) 0.28±0.19 0.05±0.01 0.00±0.00 0.40±0.06 0.71 6.20
[111In-DOTA, Nle15]-minigastrin 11 4 h (n=3) 0.80±0.43 0.07±0.02 0.01±0.01 0.35±0.03 2.25 12.3
24 h (n=3) 0.24±0.16 0.01±0.01 0.00±0.00 0.35±0.07 0.70 20.0
Uptake as percentage of injected activity per gram tissue, mean value ± SD
n Number of tested animals
* p=0.85 vs. [111 In-DTPA]-minigastrin 0; ** p<0.01 vs. [111 In-DTPA]-minigastrin 0; *** p=0.04 vs. unblocked [111 In-DOTA]-minigastrin 9;
**** p<0.01 vs. unblocked [111 In-DOTA]-minigastrin 11
a Coinjection of 100 μg DOTA-minigastrin 11
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charge (r=0.96; Fig. 3d). Uptake in gastrin receptor-negative
tissues, e.g. the kidneys, was not significantly influenced by
excess of blocking agent (Table 4). The resulting tumour-to-
kidney ratios 24 h post-injection were in the following, in
increasing order (Table 4): [111In-DTPA]-minigastrin 0
(0.05), [111In-DOTA]-minigastrin 9 (0.37), [111In-DOTA,
Nle15]-minigastrin 11 (0.70), [111In-DOTAGA]-minigastrin
11 (0.71), [111In-DOTA]-minigastrin 10 (0.73) and [111In-
DOTA]-minigastrin 11 (0.99). The 24-h tumour uptake
values were, except for [111In-DOTA]-minigastrin 11, lower
than the 4-h uptakes, but the decrease was not significant
(0.68≥p≥0.20).
SPECT/CT imaging
The combined SPECT/CT image clearly showed the
accumulation of the radiolabelled compounds in the tumour
(Fig. 4).
Fig. 4 Coregistered SPECT/CT
images of a Lewis rat bearing an
AR4-2J tumour (a: circle) after
application of 0.1 nmol
(1.1 MBq) [111In-DOTA]-
minigastrin 11. Three-
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Discussion
DTPA-coupled minigastrin and CCK derivatives have
previously been employed for labelling with radiometals
[19, 21, 22]; however, the acyclic structure of DTPA led to
a high rate of decomplexation of the radioisotopes. This
instability restricted the therapeutic use of these radio-
peptides [23]. Contrary to the acyclic chelator DTPA, the
macrocyclic chelators DOTA and DOTAGA offer higher
kinetic inertness and thereby prevent significant decom-
plexation [34].
Coupling to macrocyclic chelators resulted in minigas-
trin derivatives with the potential of a stable complexation
of α- and β-emitting radiometals. Furthermore, decreasing
the number of glutamic acid residues of the gastrin
derivatives significantly increased the tumour-to-kidney
ratio. These properties allow reduction of the undesired
uptake of the radionuclide into non-target organs during
radiopeptide therapy.
In this study, we successfully coupled both DOTA and
DOTAGA to the gastrin derivatives, retaining a high
binding affinity and receptor-specific internalisation capac-
ity. The in vivo studies revealed low intestinal retention of
our compounds, which indicates a low hepatobiliary
excretion.
Methionine-containing radiopeptides like gastrin com-
monly undergo auto-oxidation to sulfoxides during synthe-
sis and more strikingly during radiolabelling. This effect is
particularly observed after labelling with α- and β-emitting
radionuclides, which frequently cause oxidation of thio-
ether-containing amino acids via radiolysis [35]. On the one
hand, this process can be suppressed by the addition of
radical scavengers such as gentisic acid, ascorbic acid or
methionine to the labelling solution [36]. On the other
hand, the occurrence of auto-oxidation can be avoided by
substitution of methionine with methionine mimics like
methionine-sulfone, methionine-sulfoxide, norleucine or
others [37]. However, in this study, replacement of
methionine resulted in a distinct loss of binding affinity to
the gastrin receptor, except for the norleucine derivative.
This loss was considerable after employing isoleucine,
methionine-sulfone or methionine-sulfoxide, respectively.
Hence, these compounds, except the norleucine derivative,
are unsuitable for receptor targeting.
Our results indicate that the number of negative charges of
the N-terminally bound Glu residues in the sequence of
minigastrin has a positive influence on metabolic stability and
on binding affinity. We also used DOTAGA, among other
reasons like fast labelling kinetics [25], to study if a chelate-
based negative charge has a similar effect. The additional
negative charge did also enhance the metabolic stability.
Kidney uptake of radiolabelled peptides by tubular
reabsorption often restricts the maximum therapeutic dose
[38] and, therefore, is the major limitation in radiopeptide
therapy [39, 40]. Thus, reduction of kidney uptake is
essential to improve the efficacy of radiopeptide therapy.
On the one hand, coinjection of polyglutamic acid was
shown to reduce the accumulation of DTPA-minigastrin 0
in the kidneys up to a factor of ten [41]; on the other hand,
previous oral communications have indicated that modifi-
cation of the peptides might also be useful to reduce kidney
uptake [42, 43]. In our experiments, the modification of the
peptide sequence even exceeded previously reported
effects. Deletion of five glutamic acid residues in the
sequence of minigastrin 0 led to a reduction of kidney
accumulation by more than a factor of 25. This led to a
subsequent improvement of tumour-to-kidney ratio despite
the lower serum stability of the compounds. The lower
tumour uptake must be ascribed to the lower metabolic
stability. The decreased kidney uptake can potentially be
explained by the loss of the negative charges of the
glutamic acids, which may be responsible for tubular
reabsorption of radiolabelled peptides. This hypothesis is
strengthened by recent results from Behe et al. [41] of
significantly reduced kidney uptake by coinjection of
polyglutamates [41, 44]. If factors other than the overall
compound charge also have affected renal retention, this
may be shown with new series of gastrin-based peptides
having different hydrophilic spacers. Interestingly, the use
of the chelator DOTAGA did not increase the kidney
uptake as compared to DOTA despite the additional
negative charge. Among other factors, the low tumour
uptake possibly is a result of the low gastrin receptor
density on the AR4-2J cells. Notably, the reduction of the
peptide sequence had only minor influence on the binding
affinity. The slow wash out, as demonstrated by the
insignificant decrease of tumour uptake after 24 h, may
allow using the minigastrin derivatives for therapeutic
applications. Furthermore, good imaging capabilities of
gastrin-positive tissues were achieved, as shown by the
SPECT/CT images of the AR4-2J tumour-bearing Lewis
rat.
Our results have implications for further research
directed towards a higher tumour uptake of the radio-
labelled minigastrin analogues. We have shown that higher
receptor affinity, as well as higher serum stability, results in
higher tumour accumulation. Therefore, in upcoming
studies, both factors have to be considered in order to
achieve further progress in the development of radio-
labelled minigastrin analogues.
[111In-DOTA]-minigastrin 11 displayed the highest tumour-
to-kidney ratio in the animal biodistribution studies. On the
other hand, [111In-DOTA]-minigastrin 9 showed the highest
gastrin receptor affinity in human tissues, as well as the
highest stability of the DOTA-coupled minigastrins in
human blood serum. Which of the present compounds will
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offer the greatest benefit to the patient, however, remains
elusive to the first clinical trials.
In conclusion, our modified minigastrins show improved
tumour-to-kidney ratios, while the coupling with DOTA
and DOTAGA provides a high radiometal complex stabil-
ity. These properties make these derivates favourable for
clinical studies of gastrin receptor-positive tumours. Nev-
ertheless, further developments leading to a higher meta-
bolic stability should improve the bioavailability of the
radiopharmaceutical.
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